ABBV · News · 20261106N

Immunology Product Demand and Expansion

AbbVie Inc. · 2026-11-06 · Importance 38 · Surprise 24

Skyrizi and Rinvoq together account for nearly half of AbbVie’s total sales and are growing significantly faster than the company overall. Their growth is offsetting declines in older drugs, including Humira and Imbruvica, amid competition and pricing pressure. The reporting identifies continued growth in Skyrizi and Rinvoq as important to AbbVie’s performance in a competitive market.